IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Position Decreased by TD Asset Management Inc

Key Points

• TD Asset Management Inc reduced its holdings in IDEAYA Biosciences by 46.3%, selling 30,254 shares, and now owns 35,036 shares valued at approximately $574,000.
• Analysts have mixed ratings for IDEAYA Biosciences, with 10 buy ratings against 3 hold ratings, while the average target price sits at $48.09.
• IDEAYA reported a quarterly EPS of ($0.82), missing expectations by $0.07, compared to a loss of ($0.53) per share in the same quarter last year.

TD Asset Management Inc lowered its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 46.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 35,036 shares of the company's stock after selling 30,254 shares during the period. TD Asset Management Inc's holdings in IDEAYA Biosciences were worth $574,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. CWM LLC grew its stake in IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after purchasing an additional 1,814 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in IDEAYA Biosciences during the fourth quarter valued at approximately $47,000. Signaturefd LLC lifted its holdings in IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after buying an additional 2,271 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in IDEAYA Biosciences by 46.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after buying an additional 2,112 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in shares of IDEAYA Biosciences by 33.2% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,560 shares of the company's stock worth $189,000 after acquiring an additional 2,884 shares in the last quarter. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Stock Up 0.2%

NASDAQ IDYA traded up $0.06 on Friday, hitting $22.47. The stock had a trading volume of 191,776 shares, compared to its average volume of 1,152,633. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $40.74. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -5.93 and a beta of 0.09. The company's 50-day moving average is $22.42 and its two-hundred day moving average is $20.38.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. During the same quarter in the previous year, the business posted ($0.68) earnings per share. The company's revenue was up NaN% on a year-over-year basis. On average, sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on IDYA shares. Wells Fargo & Company started coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target on the stock. TD Cowen started coverage on shares of IDEAYA Biosciences in a research note on Tuesday, July 22nd. They set a "buy" rating for the company. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their target price for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. JPMorgan Chase & Co. lifted their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the company an "overweight" rating in a report on Monday, July 28th. Finally, The Goldman Sachs Group raised shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective for the company in a research report on Thursday, July 10th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $48.09.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.